RAPT Therapeutics to Participate in Upcoming Investor Conferences
Leerink Global Healthcare Conference – Fireside chat on Tuesday, March 11, 2025 at 3:40 p.m. ET
Barclays 27th Annual Global Healthcare Conference – Fireside chat on Wednesday, March 12, 2025 at 10:30 a.m. ET
To access the live webcasts or subsequent archived recordings of the discussions, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.
About RAPT Therapeutics, Inc.RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.
RAPT Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com
RAPT Media Contact:Aljanae Reynoldsareynolds@wheelhouselsa.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Stock market today: Nasdaq, Dow, S&P 500, Nasdaq futures jump as Big Tech earnings, trade deals lift spirits
S&P 500 and Nasdaq futures surged on Thursday, setting sights on fresh record highs after strong Meta (META) and Microsoft (MSFT) earnings boosted faith in a payoff from Big Tech's massive AI investments. Contracts on the tech-heavy Nasdaq 100 (NQ=F) climbed roughly 1.4%, while those on the S&P 500 (ES=F) rose almost 1%. Dow Jones Industrial Average futures (YM=F) lagged, up 0.3%. Meta shares shot up 12% in premarket, as investors welcomed its earnings beat and stronger-than-expected guidance even as it ramps up its AI spending spree. Microsoft stock jumped over 8% after its impressive results, on track to make the company the second in the world to reach a $4 trillion market valuation. Markets are now looking to after-hours results from their "Magnificent Seven" peers Apple (AAPL) and Amazon (AMZN) for reasons to keep the rally going. On the macro front, investors will get another clue as to the possible direction of interest rates with the release of the Federal Reserve's preferred inflation gauge, the Personal Consumption Expenditures (PCE) index. Stocks were mixed in during the day Wednesday after the Fed held interest rates steady for its fifth-straight meeting, with two Fed governors dissenting. Following the decision, Fed Chair Jerome Powell stressed "no decisions" had been made about a September rate cut, undercutting President Trump's claim he had heard a cut was coming at policymakers' next meeting.. Meanwhile a flurry of trade deals eased trade-war fears on the eve of President Trump's deadline on Friday. A pact with South Korea announced late Wednesday sets a 15% tariff rate on its imports. US exports will face zero duties in return, and Seoul has agreed to make $350 billion in US investment and pledged to buy US energy products, Trump wrote in a social media post. A quirk in the Fed's calendar puts extra pressure on the Sept. meeting Yahoo Finance's Hamza Shaban takes a look at the Federal Reserve's next move in today's Morning Brief: Read more here on how a long wait could result in a different outlook. Good morning. Here's what's happening today. Economic data: Challenger jobs cuts (July); Personal income & spending (June); Core PCE price index; Employment cost index (second quarter); Initial jobless claims (week ending July 26) Earnings: Apple (AAPL), Amazon (AMZN), Bristol Myers Squibb (BMY), Cigna (CI), Coinbase (COIN), CVS Health (CVS), Mastercard (MA), Norwegian Cruise Line (NCLH), Reddit (RDDT), Roblox (RBLX), Roku (ROKU), Strategy (MSTR) Here are some of the biggest stories you may have missed overnight and early this morning: Trump knocks Canada as countries rush to strike trade deals Trump tariffs face another legal test on eve of deadline Apple faces 2 major threats ahead of earnings What's in the US-EU trade deal? It depends on who's talking. Fed calendar quirk raises the stakes for its Sept. meeting Meta stock surges after earnings beat, guidance surprise Microsoft on track for $4 trillion market cap after earnings beat Arm stock falls as chip ambitions shake investor confidence Trending tickers: ARM, CVS and Confluent Here are some top stocks trending on Yahoo Finance in premarket trading: Arm (ARM) stock fell 6% on Thursday before the bell following the announcement of the chip tech provider's plan to invest in its own chip development, which would bite into future profits, disappointed investors. CVS (CVS) stock jumped 7% in premarket on Thursday after the company beat Wall Street estimates for second-quarter profit. Confluent Inc (CFLT) stock rose over 20% premarket following the company's positive earnings report. The data streaming platform reported a 21% growth in subscription revenue and a 28% growth in Confluent Cloud revenue for Q2 2025. Carvana posts higher quarterly profit on record car sales Shares in Carvana (CVNA) surged over 15% in premarket trading after the online used-car seller defied expectations with strong second quarter results and outlook. Bloomberg reports: Read more here. EBay stock rises as resilient consumers fuel strong sales forecast EBay (EBAY) stock jumped on Thursday before the bell after the e-commerce company forecasted sales that topped analysts' estimates, suggesting optimism for continued consumer resilience at a time of shifting US tariff proposals. Bloomberg News reports: Read more here. AB InBev shares slide on concern over sales volumes Beer giant Anheuser-Busch InBev (BUD) stock slumped more than 9% before the bell on Thursday after reporting that its second quarter sales volumes fell more than expected due to weak demand in Brazil and China, adding to investor worries over industry growth and hitting its shares. Reuters reports: Read more here. Qualcomm on the move lower Qualcomm's (QCOM) not playing in the big-cap tech stock euphoria this morning led by Microsoft (MSFT) and Meta (META) post earnings. Its shares are down 6% premarket. The company's earnings late Wednesday were fine. But the Street is calling out a few things that are giving the bears the win, for now. This note from HSBC's Ryan Mellor this morning captures it all nicely: This is remarkable on Meta Meta's (META) stock is rocking higher in premarket, to the tune of 12% after a monster quarter. Got to love the market ignoring the capex stuff in its earnings release below, and focusing in on Meta's revenue trends (strong). "We currently expect 2025 capital expenditures, including principal payments on finance leases, to be in the range of $66-72 billion, narrowed from our prior outlook of $64-72 billion and up approximately $30 billion year-over-year at the mid-point. While the infrastructure planning process remains highly dynamic, we currently expect another year of similarly significant capital expenditures dollar growth in 2026 as we continue aggressively pursuing opportunities to bring additional capacity online to meet the needs of our artificial intelligence efforts and business operations," Meta said. Bottom line: bull market ... carry on! Microsoft earnings call: A quick take A bit of a sleepy earnings call from Microsoft (MSFT) after the close, filled with the typical Satya Nadella tech jargon. Bottom line is this: Azure sales crushed, and there was zero signs of peaking AI demand. That should be good enough for the bulls. "We expect stock to trade up given continued large Azure growth beats and a positive AI trajectory even with continued capacity constraints. We think this also bodes well for other AI infrastructure names in our coverage (Oracle (ORCL), Coreweave (CRWV)," Citi analyst Tyler Radke said. Samsung Electronics chip business fell drastically in Q2 Samsung Electronics ( saw a mammoth drop in profit from the chip-making arm of the electronics giant. Bloomberg reports: Read more here. A quirk in the Fed's calendar puts extra pressure on the Sept. meeting Yahoo Finance's Hamza Shaban takes a look at the Federal Reserve's next move in today's Morning Brief: Read more here on how a long wait could result in a different outlook. Yahoo Finance's Hamza Shaban takes a look at the Federal Reserve's next move in today's Morning Brief: Read more here on how a long wait could result in a different outlook. Good morning. Here's what's happening today. Economic data: Challenger jobs cuts (July); Personal income & spending (June); Core PCE price index; Employment cost index (second quarter); Initial jobless claims (week ending July 26) Earnings: Apple (AAPL), Amazon (AMZN), Bristol Myers Squibb (BMY), Cigna (CI), Coinbase (COIN), CVS Health (CVS), Mastercard (MA), Norwegian Cruise Line (NCLH), Reddit (RDDT), Roblox (RBLX), Roku (ROKU), Strategy (MSTR) Here are some of the biggest stories you may have missed overnight and early this morning: Trump knocks Canada as countries rush to strike trade deals Trump tariffs face another legal test on eve of deadline Apple faces 2 major threats ahead of earnings What's in the US-EU trade deal? It depends on who's talking. Fed calendar quirk raises the stakes for its Sept. meeting Meta stock surges after earnings beat, guidance surprise Microsoft on track for $4 trillion market cap after earnings beat Arm stock falls as chip ambitions shake investor confidence Economic data: Challenger jobs cuts (July); Personal income & spending (June); Core PCE price index; Employment cost index (second quarter); Initial jobless claims (week ending July 26) Earnings: Apple (AAPL), Amazon (AMZN), Bristol Myers Squibb (BMY), Cigna (CI), Coinbase (COIN), CVS Health (CVS), Mastercard (MA), Norwegian Cruise Line (NCLH), Reddit (RDDT), Roblox (RBLX), Roku (ROKU), Strategy (MSTR) Here are some of the biggest stories you may have missed overnight and early this morning: Trump knocks Canada as countries rush to strike trade deals Trump tariffs face another legal test on eve of deadline Apple faces 2 major threats ahead of earnings What's in the US-EU trade deal? It depends on who's talking. Fed calendar quirk raises the stakes for its Sept. meeting Meta stock surges after earnings beat, guidance surprise Microsoft on track for $4 trillion market cap after earnings beat Arm stock falls as chip ambitions shake investor confidence Trending tickers: ARM, CVS and Confluent Here are some top stocks trending on Yahoo Finance in premarket trading: Arm (ARM) stock fell 6% on Thursday before the bell following the announcement of the chip tech provider's plan to invest in its own chip development, which would bite into future profits, disappointed investors. CVS (CVS) stock jumped 7% in premarket on Thursday after the company beat Wall Street estimates for second-quarter profit. Confluent Inc (CFLT) stock rose over 20% premarket following the company's positive earnings report. The data streaming platform reported a 21% growth in subscription revenue and a 28% growth in Confluent Cloud revenue for Q2 2025. Here are some top stocks trending on Yahoo Finance in premarket trading: Arm (ARM) stock fell 6% on Thursday before the bell following the announcement of the chip tech provider's plan to invest in its own chip development, which would bite into future profits, disappointed investors. CVS (CVS) stock jumped 7% in premarket on Thursday after the company beat Wall Street estimates for second-quarter profit. Confluent Inc (CFLT) stock rose over 20% premarket following the company's positive earnings report. The data streaming platform reported a 21% growth in subscription revenue and a 28% growth in Confluent Cloud revenue for Q2 2025. Carvana posts higher quarterly profit on record car sales Shares in Carvana (CVNA) surged over 15% in premarket trading after the online used-car seller defied expectations with strong second quarter results and outlook. Bloomberg reports: Read more here. Shares in Carvana (CVNA) surged over 15% in premarket trading after the online used-car seller defied expectations with strong second quarter results and outlook. Bloomberg reports: Read more here. EBay stock rises as resilient consumers fuel strong sales forecast EBay (EBAY) stock jumped on Thursday before the bell after the e-commerce company forecasted sales that topped analysts' estimates, suggesting optimism for continued consumer resilience at a time of shifting US tariff proposals. Bloomberg News reports: Read more here. EBay (EBAY) stock jumped on Thursday before the bell after the e-commerce company forecasted sales that topped analysts' estimates, suggesting optimism for continued consumer resilience at a time of shifting US tariff proposals. Bloomberg News reports: Read more here. AB InBev shares slide on concern over sales volumes Beer giant Anheuser-Busch InBev (BUD) stock slumped more than 9% before the bell on Thursday after reporting that its second quarter sales volumes fell more than expected due to weak demand in Brazil and China, adding to investor worries over industry growth and hitting its shares. Reuters reports: Read more here. Beer giant Anheuser-Busch InBev (BUD) stock slumped more than 9% before the bell on Thursday after reporting that its second quarter sales volumes fell more than expected due to weak demand in Brazil and China, adding to investor worries over industry growth and hitting its shares. Reuters reports: Read more here. Qualcomm on the move lower Qualcomm's (QCOM) not playing in the big-cap tech stock euphoria this morning led by Microsoft (MSFT) and Meta (META) post earnings. Its shares are down 6% premarket. The company's earnings late Wednesday were fine. But the Street is calling out a few things that are giving the bears the win, for now. This note from HSBC's Ryan Mellor this morning captures it all nicely: Qualcomm's (QCOM) not playing in the big-cap tech stock euphoria this morning led by Microsoft (MSFT) and Meta (META) post earnings. Its shares are down 6% premarket. The company's earnings late Wednesday were fine. But the Street is calling out a few things that are giving the bears the win, for now. This note from HSBC's Ryan Mellor this morning captures it all nicely: This is remarkable on Meta Meta's (META) stock is rocking higher in premarket, to the tune of 12% after a monster quarter. Got to love the market ignoring the capex stuff in its earnings release below, and focusing in on Meta's revenue trends (strong). "We currently expect 2025 capital expenditures, including principal payments on finance leases, to be in the range of $66-72 billion, narrowed from our prior outlook of $64-72 billion and up approximately $30 billion year-over-year at the mid-point. While the infrastructure planning process remains highly dynamic, we currently expect another year of similarly significant capital expenditures dollar growth in 2026 as we continue aggressively pursuing opportunities to bring additional capacity online to meet the needs of our artificial intelligence efforts and business operations," Meta said. Bottom line: bull market ... carry on! Meta's (META) stock is rocking higher in premarket, to the tune of 12% after a monster quarter. Got to love the market ignoring the capex stuff in its earnings release below, and focusing in on Meta's revenue trends (strong). "We currently expect 2025 capital expenditures, including principal payments on finance leases, to be in the range of $66-72 billion, narrowed from our prior outlook of $64-72 billion and up approximately $30 billion year-over-year at the mid-point. While the infrastructure planning process remains highly dynamic, we currently expect another year of similarly significant capital expenditures dollar growth in 2026 as we continue aggressively pursuing opportunities to bring additional capacity online to meet the needs of our artificial intelligence efforts and business operations," Meta said. Bottom line: bull market ... carry on! Microsoft earnings call: A quick take A bit of a sleepy earnings call from Microsoft (MSFT) after the close, filled with the typical Satya Nadella tech jargon. Bottom line is this: Azure sales crushed, and there was zero signs of peaking AI demand. That should be good enough for the bulls. "We expect stock to trade up given continued large Azure growth beats and a positive AI trajectory even with continued capacity constraints. We think this also bodes well for other AI infrastructure names in our coverage (Oracle (ORCL), Coreweave (CRWV)," Citi analyst Tyler Radke said. A bit of a sleepy earnings call from Microsoft (MSFT) after the close, filled with the typical Satya Nadella tech jargon. Bottom line is this: Azure sales crushed, and there was zero signs of peaking AI demand. That should be good enough for the bulls. "We expect stock to trade up given continued large Azure growth beats and a positive AI trajectory even with continued capacity constraints. We think this also bodes well for other AI infrastructure names in our coverage (Oracle (ORCL), Coreweave (CRWV)," Citi analyst Tyler Radke said. Samsung Electronics chip business fell drastically in Q2 Samsung Electronics ( saw a mammoth drop in profit from the chip-making arm of the electronics giant. Bloomberg reports: Read more here. Samsung Electronics ( saw a mammoth drop in profit from the chip-making arm of the electronics giant. Bloomberg reports: Read more here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in a conference call on August 7, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call. Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia's website at beginning on August 7, 2025, at 12 p.m. ET. About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @ ChavesSenior Manager, Investor
Yahoo
7 minutes ago
- Yahoo
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
CHICAGO, July 31, 2025--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Thursday, August 7, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, August 21, 2025 at US:1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 520958. To join the webcast, please visit "Events" on investor relations page of the Company's website at or use this link: About Xeris Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing's syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and a gastrointestinal motility inhibitor when used during radiology exams as a diagnostic aid; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for the treatment of hypothyroidism, as well as multiple early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit or follow us on X, LinkedIn, or Instagram. View source version on Contacts Xeris Investor Contact Allison WeySenior Vice President, Investor Relations and Corporate Communicationsawey@ Sign in to access your portfolio
